Androgen Replacement Therapy Market Size, Trends, Shares, Insights and Forecast – 2018-2026


Posted May 31, 2021 by SANJAYCMI

Androgen Replacement Therapy Market Report- 2026 Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
Global Androgen Replacement Therapy Market, by Product Type (Testosterone Creams/Gels, Testosterone Patches, Testosterone Injections, Testosterone Implants, and Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,965.5 million in 2021 and is expected to exhibit a CAGR of 7.8% during the forecast period (2021-2028).

Product approval by regulatory authorities is expected to drive growth of the global androgen replacement therapy market during the forecast period. For instance, in October 2018, Antares Pharma received the U.S. FDA approval for XYOSTED (testosterone enanthate) injection. XYOSTED is the first U.S. FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector. XYOSTED has been approved in three dosage strengths- 50 mg, 75 mg, and 100 mg, and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Key players are focused on development and launch of new advanced androgen replacement therapies in the market, which is expected to contribute significantly to the androgen replacement therapy market growth. For instance, in October 2018, Perrigo Company plc. announced the launch of an AB-rated generic version of Androgel Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g packet, and 20.25mg/1.25g actuation pump).

Global Androgen Replacement Therapy Market - Impact of Coronavirus (COVID – 19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 146 million cases and 3.1 million deaths due to coronavirus (COVID-19) were reported up till April 25th, 2021 across the globe.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3787

The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors which has been majorly affected by the pandemic. The lockdown in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient’s visits among others.

Moreover, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. The COVID-19 pandemic has affected the economy in three main ways: 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets.

Supply chain and manufacturing activities in India, China, the U.S., and others have been disrupted due to lockdowns. Whereas, countries such as Thailand, Indonesia, Singapore, and others are facing problems with transportation of drugs and medications. The COVID-19 pandemic is expected to slightly disrupt the R&D activities in the androgen replacement therapy market.

Browse 39 Market Data Tables and 22 Figures spread through 191 Pages and in-depth TOC on Global Androgen Replacement Therapy Market, by Product Type (Testosterone Creams/Gels, Testosterone Patches, Testosterone Injections, Testosterone Implants, and Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787

Several market players are focused on acquisition of commercial rights to expand their product portfolio and gain maximum share of market. For instance, in April 2016, Aytu BioScience, Inc., announced the exclusive licensing of its third commercial-stage urology product in just 11 months, with the execution of a long-term, exclusive license agreement with an affiliate of Acerus Pharmaceuticals Corporation for the U.S. commercial rights to Natesto (testosterone) Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA), as a replacement therapy for men diagnosed with hypogonadism.

Key Takeaways of the Androgen Replacement Therapy Market:

The global androgen replacement therapy market is expected to exhibit a CAGR of 7.8% over the forecast period (2021-2028), owing to growth in potential markets, especially in Europe. While, North America accounted for the major market share over the forecast period (2021 -2028).

Market players are indulged in launching of products, which is expected to drive growth of the global androgen replacement therapy market over the forecast period. For instance, in April 2020, Xiromed LLC launched Testosterone Gel 1.62% Metered Dose Pump (20.25mg/1.25g pump actuation), an AB-rated generic version of AndroGel 1.62%. AndroGel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Some of the major players operating in the global androgen replacement therapy market include AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Plc., Eli Lilly and Company, Kyowa Kirin International Plc., Novartis International AG, Pfizer Inc., Clarus Therapeutics, Inc., Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Sawai pharmaceutical Co., Ltd., Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., and Simple Pharma.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3787

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags androgen replacement therapy , androgen replacement therapy market analysis , androgen replacement therapy market outlook
Last Updated May 31, 2021